Ignite Creation Date:
2024-07-17 @ 11:44 AM
Last Modification Date:
2024-10-26 @ 3:34 PM
Study NCT ID:
NCT06487429
Status:
RECRUITING
Last Update Posted:
2024-07-05
First Post:
2024-06-27
Brief Title:
Short Course Radiotherapy With Sequential Disitamab Vedotin Combined With S-1 and Sintilimab as Whole Course Neoadjuvant Therapy for HER2 Expressed Locally Progressive Gastric Cancer
Sponsor:
Wuhan Union Hospital China
Organization:
Wuhan Union Hospital China
Organization Data
Organization:
Wuhan Union Hospital China
Class:
OTHER
Study ID:
RCVDGIIIR015
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Wuhan Union Hospital China
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| RemeGen Co Ltd | INDUSTRY |